These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 38819961)
1. Clinical features and prognosis of idiopathic inflammatory myopathies with coexistent multiple myositis-specific antibodies. Liang X; Wu J; Ren H; Li M; Huang C; Guo JG; Li D; Li J; Zhu J Clin Exp Rheumatol; 2024 May; ():. PubMed ID: 38819961 [TBL] [Abstract][Full Text] [Related]
2. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China. Wen L; Chen X; Cheng Q; Nie L; Xu J; Yan T; Zhang X; Yang H; Sun W; Liu L; Xue J; Du Y Clin Rheumatol; 2022 Nov; 41(11):3419-3427. PubMed ID: 35859245 [TBL] [Abstract][Full Text] [Related]
5. The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review. Teel A; Lu J; Park J; Singh N; Basharat P Semin Arthritis Rheum; 2022 Dec; 57():152088. PubMed ID: 36116345 [TBL] [Abstract][Full Text] [Related]
6. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases]. Xie MM; Yan X; Li H; Ding JJ; Gui XH; Liu Y; Wang YS; Chen ZY; Cai HR Zhonghua Jie He He Hu Xi Za Zhi; 2018 Aug; 41(8):616-621. PubMed ID: 30138971 [No Abstract] [Full Text] [Related]
8. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease. Gui X; Shenyun S; Ding H; Wang R; Tong J; Yu M; Zhao T; Ma M; Ding J; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y Rheumatology (Oxford); 2022 Nov; 61(11):4570-4578. PubMed ID: 35148366 [TBL] [Abstract][Full Text] [Related]
9. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. Gupta L; Naveen R; Gaur P; Agarwal V; Aggarwal R Semin Arthritis Rheum; 2021 Feb; 51(1):113-120. PubMed ID: 33360322 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance of myositis-specific autoantibodies. Nakashima R Immunol Med; 2018 Sep; 41(3):103-112. PubMed ID: 30938275 [TBL] [Abstract][Full Text] [Related]
11. The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients. Chen X; Zhang L; Jin Q; Lu X; Lei J; Peng Q; Wang G; Ge Y Front Immunol; 2022; 13():987841. PubMed ID: 36110863 [TBL] [Abstract][Full Text] [Related]
12. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort. Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X Front Immunol; 2022; 13():879266. PubMed ID: 35603153 [TBL] [Abstract][Full Text] [Related]
13. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology. Gómez GN; Pérez N; Braillard Poccard A; Gómez RA; Costi AC; García MA; Viola M; Benitez A; Aciar MM; Crespo Espíndola M; Yucra D; Cosatti MA; Pisoni C; Capelusnik D; Lojo MN; Barrios BI; Rivero M; Kisluk B; Granel A Clin Rheumatol; 2021 Nov; 40(11):4473-4483. PubMed ID: 34159491 [TBL] [Abstract][Full Text] [Related]
14. Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease. Hannah JR; Lawrence A; Martinovic J; Naqvi M; Chua F; Kouranos V; Ali SS; Stock C; Owens C; Devaraj A; Pollard L; Agarwal S; Atienza-Mateo B; González-Gay MA; Patel A; West A; Tinsley K; Robbie H; Lams B; Wells AU; Norton S; Galloway J; Renzoni EA; Gordon PA Rheumatology (Oxford); 2024 Nov; 63(11):3080-3090. PubMed ID: 38039151 [TBL] [Abstract][Full Text] [Related]
15. Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients. Li Y; Gao X; Li Y; Jia X; Zhang X; Xu Y; Gan Y; Li S; Chen R; He J; Sun X Front Med (Lausanne); 2020; 7():363. PubMed ID: 32850886 [No Abstract] [Full Text] [Related]
16. Long-Term Outcomes and Prognosis Factors in Patients With Idiopathic Inflammatory Myopathies Based on Myositis-Specific Autoantibodies: A Single Cohort Study. Jiang W; Shi J; Yang H; Tian X; Yang H; Chen Q; Zhang L; Peng Q; Wang G; Lu X Arthritis Care Res (Hoboken); 2023 May; 75(5):1175-1182. PubMed ID: 35921214 [TBL] [Abstract][Full Text] [Related]
17. Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1γ antibodies. Ueda-Hayakawa I; Tonomura K; Maekawa A; Kaneda E; Arase N; Fujimoto M J Dermatol; 2023 Aug; 50(8):1058-1062. PubMed ID: 36890683 [TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665 [TBL] [Abstract][Full Text] [Related]
19. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome. Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X Front Immunol; 2022; 13():845988. PubMed ID: 35320936 [TBL] [Abstract][Full Text] [Related]
20. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]